Figure 3
Gene transfection efficiency and cytotoxicity of CeO2/DODAB, Lipofectamine 2000, DOTAP, DEAE-Deaxtran and calcium phosphate in HEK293, MCF-7 and HepG2 cells.
(a–c) Quantification of GFP-positive cells by flow cytometry analysis after transfection with pEGFPN1 in HEK293, MCF-7 and HepG2 cells respectively; (d) quantification of RFP-positive cells by flow cytometry analysis after transfection with pTRIPZ in HEK293 cells. All values are expressed as mean ± SD. *p < 0.05, **p < 0.01 and ***p < 0.001 versus the CeO2/DODAB group; (e–g) cell viability relative to the control (100%) in HEK293, MCF-7 and HepG2 cells respectively. Cells were treated with different transfection agents at the same concentration that was used for transfection for 6 hrs and cell viability was measured after 48 hrs using the Cell Counting Kit-8 (CCK-8). All values are expressed as mean ± SD. *p < 0.05, **p < 0.01 and **p < 0.01 versus the non-treated group; (h–j) Transfection Index (the product of percentage transfection and viability) for pEGFP transfection in HEK293, MCF-7 and HepG2 cells respectively. In HEK293 cells, for CeO2/DODAB group, the cell viability was taken 100% instead of 120%. (k) Transfection Index (the product of percentage transfection and viability) for pTRIPZ transfection in HEK293 cells. All values are expressed as mean ± SD. *p < 0.05, **p < 0.01 and ***p < 0.001 versus the CeO2/DODAB group.
